Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications-Reference-Cited by-同舟云学术

Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications

Published:2024-04-02 Issue:7 Volume:67 Page:5185-5215
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Yuming¹²,Shan Lianhai³,Tang Wentao¹,Ge Yating¹,Li ChengXian¹,Zhang Jifa¹^ORCID

Affiliation:

1. Department of Neurology, Neuro-system and Multimorbidity Laboratory and State Key Laboratory of Biotherapy and Cancer Center and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China

2. West China College of Medicine, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China

3. School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031 Sichuan, China

Funder

National Natural Science Foundation of China

Sichuan Province

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00312

Reference154 articles.

1. Role of CDK/cyclin complexes in transcription and RNA splicing

2. Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro

3. Identification of a Cyclin Subunit Required for the Function ofDrosophila P-TEFb

4. Targeting cyclin-dependent kinase 9 in cancer therapy

5. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects;Journal of Medicinal Chemistry;2024-09-10

2. Inhibitors and PROTACs of CDK2: challenges and opportunities;Expert Opinion on Drug Discovery;2024-07-12